Endogenous kynurenines as targets for drug discovery and development

By T. Stone, L. Darlington. Nature reviews. Drug discovery, 2002

767 citations recorded by the source corpus.

Subfields: Behavioral Neuroscience, Biological Psychiatry, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/1523cbf5c52b116756612bbec1edc2384f739ae5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Behavioral Neuroscience

1. Michael Maes
2. J. Cryan
3. Ted G. Dinan
4. A. Mellor
5. D. Munn
6. Jonathan P. Godbout
7. G. Clarke
8. Michael R. Irwin

In Biological Psychiatry

1. J. Cryan
2. Ted G. Dinan
3. G. Clarke
4. P. Kennedy
5. D. Munn
6. Michael Maes
7. A. Mellor
8. M. Wichers

In Psychiatry and Mental health

1. A. Mellor
2. D. Munn

Citations in the corpus

• Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia (2008, background): “High levels of 3HK and QUIN induce neuronal damage through oxidative stress [33] and over stimulation of N-methyl-D-aspartate (NMDA) receptors [34,35].”
• Indoleamine 2,3-dioxygenase and tumor-induced tolerance. (2007, background): “IDO catalyzes the rate-limiting step of tryptophan degradation along the kynurenine pathway (12), and both the reduction in local tryptophan concentration and the production of immunomodulatory tryptophan metabolites contribute to the immunosuppressive effects of IDO (Figure 1).”
• Cytokines and major depression. (2005, background): “Cytokines, such as IL-1 and IFN-g which are secreted during peripheral immune responses, may reduce the TRP/CAA ratio by inducing IDO as well as stimulating the utilization of TRP and other peripheral amino acids for synthesis of positive APPs (Kubera and Maes, 2000; Stone and Darlington, 2002).”
• Kynurenine pathway metabolism and the microbiota‐gut‐brain axis (2017, background): “…and kynurenic acid are of particular interest for neurogastroenterology as they are neuroactive metabolites that act on N -methyl-D-aspartate (NMDA) and alpha7 (α7) nicotinic acetylcholine receptors in the CNS and ENS (Perkins and Stone, 1982; Stone and Darlington, 2002; Stone and Perkins, 1981).”
• AN INTERACTION BETWEEN KYNURENINE AND THE ARYL HYDROCARBON RECEPTOR CAN GENERATE REGULATORY T CELLS, (2010, background): “limiting step of tryptophan degradation along the kynurenine pathway (27).”
• Ido expression by dendritic cells: tolerance and tryptophan catabolism (2004, background): “Each enzyme catalyses the same reaction, oxidative cleavage of the 2,3 double bond in the indole ring, which is the first, rate-limiting step in tryptophan catabolism by the kynurenine pathwa”
• NAD+ metabolism and the control of energy homeostasis - a balancing act between mitochondria and the nucleus (2015, background): “These enzymes are strongly overexpressed in diverse cancers, and the subsequent synthesis of kynurenines may act as potential second messengers in cancer immune tolerance (Stone and Darlington, 2002), possibly through binding to the aryl hydrocarbon receptor (AHR) (Bessede et al.”
• Influence of Tryptophan and Serotonin on Mood and Cognition with a Possible Role of the Gut-Brain Axis (2016, background): “As noted, the synthesis of kynurenine accounts for approximately 90% of tryptophan metabolism [5].”